Varenicline-induced psychotic depressive episode in a patient with bipolar disorder
Author(s) -
Bılge Burçak Annagür,
Yasin Bez
Publication year - 2011
Publication title -
therapeutic advances in psychopharmacology
Language(s) - English
Resource type - Journals
eISSN - 2045-1261
pISSN - 2045-1253
DOI - 10.1177/2045125311430111
Subject(s) - varenicline , psychiatry , bipolar disorder , schizophrenia (object oriented programming) , medicine , vulnerability (computing) , major depressive disorder , psychosis , smoking cessation , psychology , mood , nicotine , computer science , computer security , pathology
Varenicline is a relatively novel medication for smoking cessation. Increased neuropsychiatric symptoms have been reported with its use and it is listed among drugs with a black box warning. History of a psychiatric diagnosis is suggested to be a vulnerability factor for the development of some psychiatric side effects with its use. However, empirical evidence to support this point is very limited. Here, we report the case of a bipolar patient who developed a depressive episode with psychotic features immediately after varenicline use. Clinicians should be careful about the varenicline-induced neuropsychiatric effects. Healthcare professionals can provide an important role in helping to prevent and manage worsening psychiatric symptoms.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom